Review: Cardioncology: State of the heart

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 680-687

  Todaro, Maria Chiara ^a   Oreto, Lilia ^a   Qamar, Rubina ^b   Paterick, Timothy E ^c   Carerj, Scipione ^a   Khandheria, Bijoy K ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Advanced Healthcare   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; Early detection; Left ventricular dysfunction

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOTOXIN;

ANIMAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHEMOTHERAPY; DRUG EFFECT; EARLY DETECTION; HEART; HEART LEFT VENTRICLE FAILURE; HUMAN; NEOPLASM; REVIEW;

CARDIOTOXICITY; CHEMOTHERAPY; EARLY DETECTION; LEFT VENTRICULAR DYSFUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; HEART; HUMANS; NEOPLASMS;

EID: 84885316490     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.133     Document Type: Review

References (83)

1. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure. Eur J Heart Fail 2011;13:1-10.
2. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47.
4. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia In childhood. N Engl J Med 1991;324:808-15.
5. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
6. Von Hoff DD, Layard M, Rozencweig M, Muggia FM. Time relationship between last dose of daunorubicin and congestive heart failure. Cancer Treat Rep 1977;61: 1411-30.
7. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005;131:561-78.
8. Stoodley PW, Richards DA, Hui R, et al. Two-dimensional myocardial strain Imaging detects changes In left ventricular systolic function Immediately after anthracycline chemotherapy. Eur J Echocardiogr 2011;12:945-52.
9. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubucin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
10. Puma N, Ruggiero A, Ridola V, et al. Anthracycline-related cardiotoxicity: risk factors and therapeutic options In childhood cancers. Signa Vitae 2008;3:30-4.
11. Jurcut R,Wildiers H, Ganame J, et al. Strain rate Imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy In elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-9.
12. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity In cancer patients.Cochrane Database Syst Rev 2010;3 [CD005006].
13. van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC. Cumulative Incidence and risk factors of mitoxantrone-induced cardiotoxicity In children: a systematic review. Eur J Cancer 2004;40:643-52.
14. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
15. Quezado ZM, Wilson WH, Cunnion RE, et al. high-dose Ifosfamide Is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31-6.
16. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
17. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37: 1590-8.
18. Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity In breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007;7: 67-71.
19. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009;14:1-11.
20. Sengupta PP, Northfelt DW, Gentile F, et al. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 2008;83:197-203.
21. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new Insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:820-7826.
22. Zambelli A, Della Porta MG, Eleuteri E, et al. Predicting and preventing cardiotoxicity In the era of breast cancer targeted therapies. Novel molecular tools for clinical Issues. Breast 2011;20:176-83.
23. Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase Inhibitor cancer therapeutics. Circulation 2008;118:84-95.
24. Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase Inhibitors Is correlated with their ability to damage myocytes In vitro. Toxicol Appl Pharmacol 2010;249:132-9.
25. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled In clinical trials. Mayo Clin Proc 2008;83:679-86.
26. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with the tyrosine kinase Inhibitor sunitinib. Lancet 2007;370:2011-9.
27. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity In patients treated with bevacizumab Is potentially reversible. J Clin Oncol 2011;29: e560-2.
28. Becker K, Erkenbrecher JF, Haussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57:475-84.
29. Lestuzzi C, Viel E, Picano E, Meneguzzo N. Coronary vasospasm as a cause of effort-related myocardial Ischemia during low-dose chronic continuous Infusion of 5-fluorouracil. Am J Med 2001;111:316-8.
30. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7:509-14.
31. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines In different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134:75-82.
32. Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990;29:1001-3.
33. Lestuzzi C, Crivellari D, Rigo F, Viel E, Meneguzzo N. Capecitabine cardiac toxicity presenting as effort angina: a case report. J Cardiovasc Med (Hagerstown) 2010;11:700-3.
34. Hasinoff BB, Patel D. Mechanisms of myocyte cytotoxicity Induced by the multikinase Inhibitor sorafenib. Cardiovasc Toxicol 2010;10:1-8.
35. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the Cardiologist needs to know. Nat Rev Cardiol 2010;7:564-75.
36. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542.
37. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
38. Miller KD, Chap Li, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine In patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
39. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
40. Raschi E, De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging Issues In the era of cardio-oncology. Intern Emerg Med 2012;7:113-31.
41. Gupta R, Maitland ML. Sunitinib, Hypertension, and heart failure: a model for kinase Inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 2011;13:430-5.
42. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of Hypertension with sorafenib In patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117-23.
43. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7.
44. Moore RA, Adel N, Riedel E, et al. high Incidence of thromboembolic events In patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011;29:3466-73.
45. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomideand lenalidomide-associated thrombosis In myeloma. Leukemia 2008;22:414-23.
46. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women In US SEER cancer registries. Lancet Oncol 2005;6:557-65.
47. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes In a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
48. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects In the heart. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl.):S77-85.
49. Lipshultz SE, Sallan SE. Cardiovascular abnormalities In long-term survivors of childhood malignancy. J Clin Oncol 1993;11:1199-203.
50. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-55.
51. Horacek JM, JaklM, Horackova J, Pudil R, Jebavy L,Maly J. Assessment of anthracyclineinduced cardiotoxicity with electrocardiography. Exp Oncol 2009;31:115-7.
52. Morganroth J, Shah RR, Scott JW. Evaluation and management of cardiac safety using the electrocardiogram In oncology clinical trials: focus on cardiac repolarization (QTc Interval). Clin Pharmacol Ther 2010;87:166-74.
53. Eidem BW. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction Is not enough. J Am Soc Echocardiogr 2008;21:1290-2.
54. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-8.
55. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, SullivanDM, Kupersmith J. Prolongation of Isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction In humans. J Am Coll Cardiol 1992;20: 62-9.
56. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler Imaging and conventional echocardiography after anthracycline treatment In adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-6.
57. Karakurt C, Koçak G, Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography In pediatric malignancy survivors after anthracycline therapy. Echocardiography 2008;25:880-7.
58. Jurcut R,Wildiers H, Ganame J, D'hooge J, Paridaens R, Voigt JU. Detection and monitoring of cardiotoxicity -what does modern Cardiology offer? Support Care Cancer 2008;16:437-45.
59. Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with Inflammatory and oxidative stress markers. Oncologist 2007;12:1124-33.
60. Hare JL, Brown JK, Leano R, Jenkins C,WoodwardN,Marwick TH. Use ofmyocardial deformation Imaging to detect preclinical myocardial dysfunction before conventional measures In patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301.
61. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline-and trastuzumabinduced cardiotoxicity In the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010;96:701-7.
62. de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, et al. ScIntigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med 2011;52: 560-71.
63. Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance Imaging -a pilot study. Am Heart J 2001;141:1007-13.
64. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I In cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54.
65. Cardinale D, SandriMT. Role of biomarkers In chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53:121-9.
66. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapyinduced cardiotoxicity In high-risk patients by angiotensin- converting enzyme Inhibition. Circulation 2006;114:2474-81.
67. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62.
68. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced Inflammation, oxidative stress, and early ventricular Impairment. Am Heart J 2010;160:487.e1-7.
69. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55: 213-20.
70. JessupM, AbrahamWT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure In Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed In collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
71. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction In patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.
72. Ammar El-Sayed M, Said SA, Suddek GM, El-Damarawy SL. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone In rats. Can J Physiol Pharmacol 2011;89:269-76.
73. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant In doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-termfollow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010;11:950-61.
74. Cvetković RS, Scott LJ. Dexrazoxane: a review of Its use for cardioprotection during anthracycline chemotherapy. Drugs 2005;65:1005-24.
75. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective Interventions for cancer patients receiving anthracyclines.Cochrane Database Syst Rev 2011;6 [CD003917].
76. Walker JR, Sharma A, Lytwyn M, et al. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. J AmSoc Echocardiogr 2011;24:699-705.
77. Tikoo K, SaneMS, Gupta C. Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates Its anti-cancer activity: potential role of tannins In cancer chemotherapy. Toxicol Appl Pharmacol 2011;251:191-200.
78. Zhu SG, Kukreja RC, Das A, Chen Q, Lesnefsky EJ, Xi L. Dietary nitrate supplementation protects against Doxorubicin-induced cardiomyopathy by Improving mitochondrial function. J Am Coll Cardiol 2011;57:2181-99.
79. Hamed S, Barshack I, Luboshits G, et al. erythropoietin Improves myocardial performance In doxorubicin-induced cardiomyopathy. Eur Heart J 2006;27:1876-83.
80. Neilan TG, Jassal DS, ScullyMF, et al. Iloprost attenuates doxorubicin-induced cardiac Injury In a murine model without compromising tumour suppression. Eur Heart J 2006;27:1251-6.
81. Miyagawa K, Emoto N, Widyantoro B, et al. Attenuation of doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis Impairment. Hypertension 2010;55:738-46.
82. AgarwalM, Phan A,Willix Jr R, BarberM, Schwarz ER. Is vitamin D deficiency associated with heart failure? A review of current evidence. J Cardiovasc Pharmacol Ther 2011;16:354-63.
83. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity In chemotherapy-treated patients. Am J Cardiol 2011;107:1375-80.